Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.
- Published In:
- Expert opinion on investigational drugs, 34(9), 655-663 (2025)
- Authors:
- Fiorucci, Stefano, Urbani, Ginevra
- Database ID:
- RPEP-10957
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10957APA
Fiorucci, Stefano; Urbani, Ginevra. (2025). Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.. Expert opinion on investigational drugs, 34(9), 655-663. https://doi.org/10.1080/13543784.2025.2546812
MLA
Fiorucci, Stefano, et al. "Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.." Expert opinion on investigational drugs, 2025. https://doi.org/10.1080/13543784.2025.2546812
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide for metabolic dysfunction-associated steatohepat..." RPEP-10957. Retrieved from https://rethinkpeptides.com/research/fiorucci-2025-tirzepatide-for-metabolic-dysfunctionassociated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.